Cognitive Neuropsychiatry is a distinguished academic journal published by Routledge Journals, Taylor & Francis Ltd, dedicated to the intersection of cognitive neuroscience and psychiatry. With a strong commitment to advancing knowledge in these rapidly evolving fields, this journal provides a platform for high-quality, peer-reviewed research that explores cognitive processes underlying psychiatric disorders. Aiming to bridge gaps between neuroscience and clinical practice, it serves as an essential resource for researchers, professionals, and students alike. As evidenced by its performance metrics, the journal ranks in the Q2 quartile for Psychiatry and Mental Health, and Q3 for Cognitive Neuroscience, showcasing its relevance and growing impact, particularly among a competitive audience. While it does not currently offer open access options, Cognitive Neuropsychiatry remains a vital outlet for disseminating impactful findings, offering insights that shape contemporary psychiatric understanding and interventions.

ARQUIVOS DE NEURO-PSIQUIATRIA is a distinguished peer-reviewed journal that has been pivotal in advancing the fields of neuropsychiatry and neurology since its inception in 1945. Published by ASSOC ARQUIVOS NEURO-PSIQUIATRIA, this journal has established itself as a vital resource for researchers, professionals, and students in Brazil and beyond, with a commitment to open access since 2000, allowing broad dissemination of its findings. It boasts an E-ISSN of 1678-4227, continues to publish high-quality research, and is recognized in Scopus rankings, which place it in the Q4 quartile in Biological Psychiatry and Q3 in both Clinical Neurology and Neurology for 2023. The journal's address, located in the heart of São Paulo, reflects its commitment to fostering scientific dialogue within Brazil's vibrant research community. By focusing on the intersection of neurology and psychiatry, ARQUIVOS DE NEURO-PSIQUIATRIA aims to enrich our understanding of complex neurological disorders and psychiatric conditions, making it essential reading for those engaged in these critical areas of health research.

MOLECULAR PSYCHIATRY, published by SpringerNature, is a premier peer-reviewed journal that has established itself as a leading platform for the dissemination of cutting-edge research in the fields of neuroscience, molecular biology, and psychiatry. With an impressive impact factor and a reputation for excellence, the journal is ranked Q1 in key categories, signifying its high academic quality and relevance. The journal’s scope spans groundbreaking studies and innovative therapeutic approaches that intersect at the molecular and cellular levels, providing invaluable insights into the biological underpinnings of psychiatric disorders. Since its inception in 1996, MOLECULAR PSYCHIATRY has evolved to support both established and emerging researchers, fostering a collaborative environment that enhances the understanding of mental health. It is committed to improving access to scientific knowledge, although it currently does not offer open access options. With its headquarters in London, the journal continues to play a pivotal role in enhancing the global dialogue on psychiatric and neurological advancements, making it an essential resource for academics and professionals dedicated to advancing mental health sciences.

Psychiatry and Clinical Psychopharmacology, an open-access journal published by AVES since 2017, is dedicated to advancing the fields of psychiatric medicine and psychopharmacology. With an ISSN of 2475-0573 and an E-ISSN of 2475-0581, this journal aims to provide a platform for disseminating innovative research and clinical findings relevant to mental health professionals and researchers. Although it currently holds a Q3 ranking in Pharmacology (medical) and a Q4 ranking in Psychiatry and Mental Health according to the 2023 category quartiles, the journal has established itself as a significant contributor to evolving discussions in these critical fields. Based in the United Kingdom, the journal encompasses diverse topics, ranging from pharmacological treatments to novel therapeutic approaches in psychiatry, thereby appealing to a broad audience of clinicians, scientists, and students. The open-access model ensures that all research is readily available, fostering an environment of collaboration and knowledge-sharing as the journal converges until 2024 to encompass the latest advancements in both pharmacology and clinical psychopharmacology.

The INTERNATIONAL JOURNAL OF NEUROSCIENCE, published by TAYLOR & FRANCIS LTD, stands as a vital resource in the field of neuroscience since its inception. With a proud history of publication from 1970 to 2024, this journal is committed to advancing knowledge in various domains of neuroscience, from fundamental research to clinical applications. It is indexed with an ISSN of 0020-7454 and an E-ISSN of 1563-5279, reflecting its wide reach and recognition. The journal maintains a respectable position in the academic landscape, categorized as Q2 in Medicine (miscellaneous) and Q3 in Neuroscience (miscellaneous) as of 2023, signifying its relevance among researchers and professionals. Although it currently does not offer open access, the journal remains a significant platform for disseminating groundbreaking research, thereby fostering collaboration and innovation within the neuroscience community. Located in the United Kingdom, the journal aims to bridge gaps in neuroscience knowledge, making it an essential reading for students, professionals, and researchers dedicated to unraveling the complexities of the nervous system.

BRAIN & DEVELOPMENT is a prestigious academic journal published by ELSEVIER, renowned for its pivotal contributions to the fields of developmental neuroscience, neurology, and pediatrics. Established in 1979, this journal has become an essential resource for researchers and clinicians alike, as it explores the complexities of brain development and associated neurological disorders in children. With an impactful focus on advancing scientific understanding, BRAIN & DEVELOPMENT is currently ranked in the Q3 quartile in Developmental Neuroscience and Clinical Neurology and Q2 in Pediatrics, reflecting its significance within the medical community. Its ISSN 0387-7604 and E-ISSN 1872-7131 underline its established presence in academic literature. While the journal does not offer open access options, it continues to be a key platform for disseminating new research findings and fostering innovation in the understanding of pediatric neurological health. The journal's commitment to quality research is further evidenced by its ongoing publication trajectory up until 2024, making it a vital source of knowledge for students, professionals, and educators in related fields.

Annals of Indian Psychiatry is a premier journal dedicated to the field of mental health and psychiatry, published by Wolters Kluwer Medknow Publications. As an Open Access journal since 2017, it provides a platform for disseminating high-quality research articles, clinical studies, and reviews that address the diverse aspects of psychiatric disorders, treatment methodologies, and mental health policy in India and beyond. The journal aims to bridge gaps in the existing literature, support practitioners with evidence-based insights, and foster dialog among researchers in the psychiatric community. With an emphasis on innovative approaches and culturally relevant practices, the Annals of Indian Psychiatry serves as a vital resource for psychiatrists, psychologists, social workers, and students engaged in clinical practice and academic research. Its commitment to improving mental health outcomes in diverse populations makes it a significant contributor to the global discourse on psychiatric health.

PSYCHIATRY AND CLINICAL NEUROSCIENCES is a leading journal in the fields of psychiatry and clinical neurology, published by Wiley. With a commendable impact factor and a position within the prestigious Q1 quartile across multiple relevant categories—including Medicine (Miscellaneous), Neurology, and Psychiatry and Mental Health—this journal stands out for its rigorous peer-reviewed content that addresses critical issues in mental health and neurological disorders. Established in 1933, the journal has a rich history of contributing impactful research that guides both clinical practice and academic inquiry. Although it is not an open-access journal, its high relevance is underscored by its Scopus rankings, with notable percentiles in Psychiatry and Neurology, making it a vital resource for researchers, clinicians, and students looking to stay abreast of the latest advancements. Located in the United Kingdom, PSYCHIATRY AND CLINICAL NEUROSCIENCES aims to bridge the gap between theory and practical application, fostering a comprehensive understanding of the complex interplay between mental health and neurological conditions.

Asia-Pacific Psychiatry is a leading academic journal published by WILEY, focused on the diverse and rapidly evolving fields of psychiatry and mental health within the Asia-Pacific region. With an ISSN of 1758-5864 and an E-ISSN of 1758-5872, this journal has been recognized for its significant impact, holding a Q1 ranking in Medicine (miscellaneous) and a Q2 ranking in Psychiatry and Mental Health as of 2023. Its commendable Scopus ranking places it at Rank #83 out of 567 in its category, highlighting its influence and relevance in contemporary research. The journal aims to facilitate the dissemination of high-quality research, reviews, and clinical insights that address mental health challenges, promote global understanding, and encourage collaboration among professionals and academics. Although it is not an open-access journal, the high impact factor underscores its value in the scholarly community, making it an essential resource for researchers, clinicians, and students dedicated to enhancing mental health practices and policies in the region and beyond.

BIPOLAR DISORDERS, published by Wiley, is a leading international journal dedicated to advancing the understanding and treatment of bipolar disorders. Since its establishment in 1999, the journal has become a vital resource in the fields of Biological Psychiatry and Psychiatry and Mental Health, currently ranked in the Q2 category for Biological Psychiatry and Q1 for Psychiatry and Mental Health as of 2023. With impressive Scopus rankings, it stands at 75th out of 567 in Psychiatry and Mental Health and 11th out of 51 in Biological Psychiatry, reflecting its influential role in shaping mental health research. The journal not only focuses on empirical studies, reviews, and clinical reports but also encourages innovative methodological advancements in understanding bipolar disorders. Although it does not offer Open Access, its extensive coverage from 1999 to 2024 ensures that practitioners, researchers, and students have access to a wealth of knowledge critical for the development of effective therapeutic interventions. For those engaging with cutting-edge research in psychiatric care, BIPOLAR DISORDERS serves as an essential platform for knowledge dissemination and academic discourse.